LU92517I2 - Delamanide et ses dérivés pharmaceutiquement acceptables - Google Patents
Delamanide et ses dérivés pharmaceutiquement acceptablesInfo
- Publication number
- LU92517I2 LU92517I2 LU92517C LU92517C LU92517I2 LU 92517 I2 LU92517 I2 LU 92517I2 LU 92517 C LU92517 C LU 92517C LU 92517 C LU92517 C LU 92517C LU 92517 I2 LU92517 I2 LU 92517I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- delamanide
- pharmaceutically acceptable
- acceptable derivatives
- derivatives
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002298259 | 2002-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92517I2 true LU92517I2 (fr) | 2014-10-13 |
Family
ID=32089299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92517C LU92517I2 (fr) | 2002-10-11 | 2014-08-13 | Delamanide et ses dérivés pharmaceutiquement acceptables |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7262212B2 (pt) |
| EP (2) | EP2570418A3 (pt) |
| JP (1) | JP4186065B2 (pt) |
| KR (1) | KR100723847B1 (pt) |
| CN (4) | CN102532162B (pt) |
| AR (4) | AR041198A1 (pt) |
| AU (1) | AU2003272979B2 (pt) |
| BE (1) | BE2014C053I2 (pt) |
| BR (1) | BRPI0314344B8 (pt) |
| CA (1) | CA2497569C (pt) |
| CY (2) | CY1113578T1 (pt) |
| DK (1) | DK1555267T3 (pt) |
| ES (1) | ES2400179T3 (pt) |
| FR (1) | FR14C0066I2 (pt) |
| HK (2) | HK1085463A1 (pt) |
| HU (1) | HUS1400046I1 (pt) |
| LU (1) | LU92517I2 (pt) |
| MX (1) | MXPA05003674A (pt) |
| MY (1) | MY139244A (pt) |
| PL (3) | PL404913A1 (pt) |
| PT (1) | PT1555267E (pt) |
| RU (1) | RU2326121C3 (pt) |
| SI (1) | SI1555267T1 (pt) |
| TW (1) | TWI347946B (pt) |
| UA (1) | UA83200C2 (pt) |
| WO (1) | WO2004033463A1 (pt) |
| ZA (1) | ZA200501033B (pt) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564713B2 (ja) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 |
| EP2644599B1 (en) | 2002-10-15 | 2014-12-10 | Otsuka Pharmaceutical Co., Ltd. | Method for preparing a 2-halo-4-nitroimidazole compound |
| EP1678185B1 (en) | 2003-10-31 | 2008-10-08 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis |
| JP4761756B2 (ja) * | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| TWI300409B (en) | 2004-02-18 | 2008-09-01 | Otsuka Pharma Co Ltd | Method for producing 4-nitroimidazole compound |
| SI1731518T1 (sl) | 2004-03-31 | 2014-11-28 | Nippon Soda Co., Ltd. | Spojina cikličen amin in sredstvo za nadzorovanje škodljivcev |
| JP4789966B2 (ja) * | 2004-04-09 | 2011-10-12 | 大塚製薬株式会社 | 医薬組成物 |
| JP4787529B2 (ja) * | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
| WO2007002057A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| RU2413504C3 (ru) * | 2005-07-28 | 2021-10-05 | Оцука Фармасьютикал Ко., Лтд. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО[2,1-b]ОКСАЗОЛА |
| JP5105818B2 (ja) * | 2005-10-05 | 2012-12-26 | 大塚製薬株式会社 | 医薬組成物 |
| TWI368509B (en) * | 2005-10-05 | 2012-07-21 | Otsuka Pharma Co Ltd | Antituberculous therapeutic drugs and kit containing the same |
| EP1932844B1 (en) | 2005-10-06 | 2015-09-02 | Nippon Soda Co., Ltd. | Cross-linked cyclic amine compounds and agents for pest control |
| TW200800268A (en) * | 2005-11-04 | 2008-01-01 | Otsuka Pharma Co Ltd | Medicinal composition showing improved drug absorbability |
| AU2006333522A1 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation |
| WO2007093557A1 (en) * | 2006-02-13 | 2007-08-23 | Laboratoires Serono S.A. | Sulfonamide derivatives for the treatment of bacterial infections |
| JP2007297305A (ja) * | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| EP2125750B1 (en) * | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| AR070301A1 (es) | 2007-05-08 | 2010-03-31 | Otsuka Pharma Co Ltd | Compuesto epoxi y metodo para producir el mismo |
| CL2008002199A1 (es) * | 2007-07-26 | 2009-10-23 | Vitae Pharmaceuticals Inc | Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras. |
| EP2185542A2 (en) * | 2007-08-15 | 2010-05-19 | Glaxo Group Limited | Substituted quinoline derivatives as h1 receptor antagonists |
| JP2011500634A (ja) * | 2007-10-16 | 2011-01-06 | グラクソ グループ リミテッド | 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体 |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| US8592409B2 (en) | 2008-01-24 | 2013-11-26 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| JP5734666B2 (ja) * | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤 |
| US8598160B2 (en) * | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| JP5538356B2 (ja) * | 2008-03-18 | 2014-07-02 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤 |
| CN101965353B (zh) * | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8138178B2 (en) * | 2008-05-01 | 2012-03-20 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009134384A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CN102119160B (zh) | 2008-07-25 | 2014-11-05 | 贝林格尔·英格海姆国际有限公司 | 11β-羟基类固醇脱氢酶1的环状抑制剂 |
| WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| WO2010127237A2 (en) * | 2009-04-30 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| BRPI0917394A2 (pt) * | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
| JP5525515B2 (ja) * | 2008-08-21 | 2014-06-18 | デイナミート ノーベル ゲゼルシャフト ミット ベシュレンクテル ハフツング エクスプロジーフシュトッフ− ウント ジステームテヒニク | ２−ハロ−４−ニトロイミダゾール及びその中間体の製造方法 |
| WO2010143007A1 (en) * | 2009-06-10 | 2010-12-16 | Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik | Method for the production of 2-halogeno-4-nitroimidazole |
| WO2010089303A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 |
| TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
| MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CN102741259B (zh) | 2009-07-31 | 2016-04-13 | 全球结核病药物研发联盟 | 硝基咪唑并噁嗪和硝基咪唑并噁唑的类似物及其用途 |
| US9198913B2 (en) | 2009-07-31 | 2015-12-01 | Global Alliance For Tb Drug Development | Nitroimidazooxazines and their uses in anti-tubercular therapy |
| CA2769359C (en) * | 2009-07-31 | 2017-03-07 | Global Alliance For Tb Drug Development | Nitroimidazooxazines and their uses in anti-tubercular therapy |
| US20120219500A1 (en) | 2009-10-26 | 2012-08-30 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic agent for infectious diseases |
| TW201200523A (en) * | 2010-01-29 | 2012-01-01 | Otsuka Pharma Co Ltd | Synthetic intermediate of oxazole compound and method for producing the same |
| GB201012209D0 (en) * | 2010-05-31 | 2010-09-08 | Ge Healthcare Ltd | In vivo imaging agent |
| JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用 |
| EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| JP2013540801A (ja) | 2010-11-02 | 2013-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝異常の治療のための組合せ医薬 |
| JP5916739B2 (ja) | 2011-04-15 | 2016-05-11 | 大塚製薬株式会社 | ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物 |
| JP2015006994A (ja) * | 2011-10-28 | 2015-01-15 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体 |
| US9572809B2 (en) | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
| FR3000064A1 (fr) * | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
| US9845330B2 (en) * | 2013-10-04 | 2017-12-19 | Council Of Scientific & Industrial Research | 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof |
| CN103524492A (zh) * | 2013-10-23 | 2014-01-22 | 中国药科大学 | 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途 |
| TWI687409B (zh) | 2014-08-28 | 2020-03-11 | 日商大塚製藥股份有限公司 | 稠合雜環化合物 |
| US9822126B1 (en) | 2014-10-21 | 2017-11-21 | Council Of Scientific & Industrial Research | Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof |
| CN105732659B (zh) * | 2014-12-12 | 2019-07-16 | 上海阳帆医药科技有限公司 | 硝基咪唑类化合物及其制备方法和在制药中的用途 |
| US10227362B2 (en) | 2015-01-29 | 2019-03-12 | Medshine Discovery Inc. | Anti-pulmonary tuberculosis nitroimidazole derivative |
| LT3275862T (lt) | 2015-03-27 | 2020-09-25 | Otsuka Pharmaceutical Co., Ltd. | 1-(4-hidroksifenil)-4-(4-trifluormetoksifenoksi)piperidino arba jo druskos gamybos būdas |
| CN106317072B (zh) * | 2015-06-17 | 2020-03-17 | 盟科医药技术(上海)有限公司 | 用于分枝杆菌感染治疗的杂环化合物及其应用 |
| CN108884044B (zh) | 2016-02-26 | 2023-01-31 | 大塚制药株式会社 | 哌啶衍生物 |
| CN105859628B (zh) * | 2016-04-19 | 2018-08-07 | 清远职业技术学院 | 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用 |
| US20190276475A1 (en) * | 2016-07-22 | 2019-09-12 | Medshine Discovery Inc. | Crystal and salt of nitroimidazole, and manufacturing method thereof |
| KR102657360B1 (ko) * | 2017-08-16 | 2024-04-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| EA202092952A1 (ru) | 2018-06-11 | 2021-03-22 | Оцука Фармасьютикал Ко., Лтд. | Содержащая деламанид композиция |
| CN109705022A (zh) * | 2018-12-28 | 2019-05-03 | 上海彩迩文生化科技有限公司 | 一种芳香胺中间体的制备方法 |
| CN112300192B (zh) * | 2019-08-02 | 2023-08-11 | 南京长澳医药科技有限公司 | 硝基咪唑类化合物及其制备方法和用途 |
| CN110483549B (zh) * | 2019-08-30 | 2021-03-05 | 沈阳药科大学 | 一种硝基咪唑吡喃类抗结核药物的制备方法 |
| CN110615800A (zh) * | 2019-10-16 | 2019-12-27 | 李丽丽 | 硝基咪唑类化合物及其制备方法和用途 |
| CN112156088B (zh) * | 2020-10-30 | 2021-08-31 | 健民药业集团股份有限公司 | 一种化合物在制备结核分枝杆菌抑制剂中的用途 |
| CN113603706A (zh) * | 2021-08-04 | 2021-11-05 | 深圳市泰力生物医药有限公司 | 德拉马尼的晶型、含有该晶型的活性药物和药物组合物 |
| CN115368252B (zh) * | 2022-09-19 | 2024-01-12 | 西北农林科技大学 | 一种4-胺基酚类衍生物及应用 |
| CN116640106B (zh) * | 2023-05-11 | 2024-03-08 | 郑州大学 | 一种苯基哌嗪类化合物及其制备方法、应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
-
2003
- 2003-10-09 AR ARP030103673A patent/AR041198A1/es active IP Right Grant
- 2003-10-09 TW TW092128165A patent/TWI347946B/zh not_active IP Right Cessation
- 2003-10-10 PL PL404913A patent/PL404913A1/pl unknown
- 2003-10-10 WO PCT/JP2003/013070 patent/WO2004033463A1/ja active Application Filing
- 2003-10-10 US US10/530,429 patent/US7262212B2/en not_active Expired - Lifetime
- 2003-10-10 PL PL409525A patent/PL409525A1/pl unknown
- 2003-10-10 EP EP12193820.3A patent/EP2570418A3/en not_active Withdrawn
- 2003-10-10 AU AU2003272979A patent/AU2003272979B2/en not_active Expired
- 2003-10-10 ES ES03754085T patent/ES2400179T3/es not_active Expired - Lifetime
- 2003-10-10 DK DK03754085.3T patent/DK1555267T3/da active
- 2003-10-10 BR BRPI0314344A patent/BRPI0314344B8/pt active IP Right Grant
- 2003-10-10 CN CN201110416170.4A patent/CN102532162B/zh not_active Expired - Lifetime
- 2003-10-10 SI SI200332254T patent/SI1555267T1/sl unknown
- 2003-10-10 CN CNB2003801017508A patent/CN100366624C/zh not_active Expired - Lifetime
- 2003-10-10 EP EP03754085A patent/EP1555267B1/en not_active Expired - Lifetime
- 2003-10-10 PL PL376157A patent/PL217919B1/pl unknown
- 2003-10-10 UA UAA200504391A patent/UA83200C2/ru unknown
- 2003-10-10 PT PT37540853T patent/PT1555267E/pt unknown
- 2003-10-10 CA CA2497569A patent/CA2497569C/en not_active Expired - Lifetime
- 2003-10-10 KR KR1020057004567A patent/KR100723847B1/ko active Protection Beyond IP Right Term
- 2003-10-10 CN CNA2007100040367A patent/CN101172981A/zh active Pending
- 2003-10-10 CN CNA2007100040371A patent/CN101255170A/zh active Pending
- 2003-10-10 MX MXPA05003674A patent/MXPA05003674A/es active IP Right Grant
- 2003-10-10 MY MYPI20033866A patent/MY139244A/en unknown
- 2003-10-10 RU RU2005114017A patent/RU2326121C3/ru active Protection Beyond IP Right Term
- 2003-10-14 JP JP2003353868A patent/JP4186065B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-03 ZA ZA200501033A patent/ZA200501033B/en unknown
-
2006
- 2006-02-03 HK HK06101486A patent/HK1085463A1/xx not_active IP Right Cessation
-
2012
- 2012-04-23 AR ARP120101394A patent/AR086485A2/es unknown
- 2012-11-21 HK HK12111863.7A patent/HK1171018A1/xx not_active IP Right Cessation
-
2013
- 2013-01-25 CY CY20131100076T patent/CY1113578T1/el unknown
- 2013-02-08 AR ARP130100408A patent/AR089950A2/es unknown
- 2013-07-15 AR ARP130102514 patent/AR091771A2/es not_active Application Discontinuation
-
2014
- 2014-08-13 LU LU92517C patent/LU92517I2/xx unknown
- 2014-08-14 HU HUS1400046C patent/HUS1400046I1/hu unknown
- 2014-09-09 BE BE2014C053C patent/BE2014C053I2/fr unknown
- 2014-09-11 FR FR14C0066C patent/FR14C0066I2/fr active Active
- 2014-09-24 CY CY2014041C patent/CY2014041I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92517I2 (fr) | Delamanide et ses dérivés pharmaceutiquement acceptables | |
| LU92513I2 (fr) | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) | |
| LU92419I2 (fr) | Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®) | |
| LU93093I2 (fr) | Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza) | |
| LU92336I2 (fr) | Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA) | |
| LU92381I2 (fr) | Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT) | |
| LU92871I2 (fr) | Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) | |
| LU93189I2 (fr) | Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ) | |
| LU92024I2 (fr) | Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR) | |
| LUC00127I1 (fr) | Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro ) | |
| LU91624I2 (fr) | Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®) | |
| IS2599B (is) | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess | |
| LU92326I2 (fr) | Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) | |
| LU92182I2 (fr) | Dapagliflozine et ses sels pharmaceutiquement acceptables | |
| LU91883I2 (fr) | Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) | |
| LU92745I2 (fr) | Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr) | |
| LU92634I2 (fr) | Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl) | |
| LU91269I2 (fr) | Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro) | |
| DE60324099D1 (de) | Arzneistoffhaltiger tampon | |
| IS2504B (is) | Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra | |
| IS7872A (is) | Pýrrólópýrimidín afleiður | |
| ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
| DK1556385T3 (da) | Heterocyclocarboxamid-derivater | |
| DK1551802T3 (da) | Indol-3-svovlderivater | |
| ATE467631T1 (de) | Chinuclidinamidderivate |